Page last updated: 2024-10-16

adenine and Cough

adenine has been researched along with Cough in 2 studies

Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aldana, G	1
Jimenez, CA	1
Moran, C	1
Byrd, JC	1
Brown, JR	1
O'Brien, S	1
Barrientos, JC	1
Kay, NE	1
Reddy, NM	1
Coutre, S	1
Tam, CS	1
Mulligan, SP	1
Jaeger, U	1
Devereux, S	1
Barr, PM	1
Furman, RR	1
Kipps, TJ	1
Cymbalista, F	1
Pocock, C	1
Thornton, P	1
Caligaris-Cappio, F	1
Robak, T	1
Delgado, J	1
Schuster, SJ	1
Montillo, M	1
Schuh, A	1
de Vos, S	1
Gill, D	1
Bloor, A	1
Dearden, C	1
Moreno, C	1
Jones, JJ	1
Chu, AD	1
Fardis, M	1
McGreivy, J	1
Clow, F	1
James, DF	1
Hillmen, P	1

Clinical Trials (7)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2019-04-11	Terminated (stopped due to Insufficient accrual)
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707]	Phase 3	391 participants (Actual)	Interventional	2012-06-30	Completed
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410]		40 participants (Actual)	Observational [Patient Registry]	2018-12-01	Completed
Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia[NCT03755947]	Phase 2	3 participants (Actual)	Interventional	2018-12-01	Completed
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895]		40 participants (Actual)	Observational	2017-07-21	Active, not recruiting
Expression of CD19 Complex in Lymphoproliferative Disorders[NCT04734470]		92 participants (Anticipated)	Observational	2021-03-31	Not yet recruiting
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798]	Phase 3	22 participants (Actual)	Interventional	2019-12-09	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

Intervention	Participants (Count of Participants)
Ibrutinib Plus Rituximab	0

OS (Overall Survival)

OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up

Intervention	months (Median)
Ofatumumab (Arm A)	65.1
Ibrutinib (Arm B)	67.7

Overall Response Rate (ORR) by Independent Review Committee (IRC)

Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled

Intervention	percentage of participants (Number)
Ofatumumab (Arm A)	4.1
Ibrutinib (Arm B)	42.6

Overall Response Rate (ORR) by Investigator

Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Intervention	percentage of participants (Number)
Ofatumumab (Arm A)	22.4
Ibrutinib (Arm B)	87.7

PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013

The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.

Intervention	months (Median)
Ofatumumab (Arm A)	8.1
Ibrutinib (Arm B)	NA

Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up

Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Intervention	months (Median)
Ofatumumab (Arm A)	8.1
Ibrutinib (Arm B)	44.1

Rate of Sustained Hemoglobin and Platelet Improvement

Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Intervention	percentage of participants (Number)
	Hgb Improvement in patient with baseline anemia	Platelet improvement in baseline thrombocytopenia
Ibrutinib (Arm B)	69.7	78.4
Ofatumumab (Arm A)	32.6	9.4

Trials

1 trial available for adenine and Cough

Article	Year
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal	2014

Other Studies

1 other study available for adenine and Cough

Article	Year
Unusual cause of sinusitis and cough. BMJ case reports, 2018, Jul-19, Volume: 2018 Topics: Adenine; Biopsy; Cough; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Midd	2018